Clinical and Transcriptional Response to the Long-Acting Interleukin-1 Blocker Canakinumab in Blau Syndrome-Related Uveitis

OBJECTIVE: To report on the clinical response to canakinumab in a patient with sporadic nucleotide-binding oligomerization domain–containing protein 2 (NOD-2)–associated pediatric granulomatous arthritis (Blau syndrome) and severe resistant panuveitis, and to describe gene expression profile changes...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Simonini, Gabriele, Xu, Zhaohui, Caputo, Roberto, De Libero, Cinzia, Pagnini, Ilaria, Pascual, Virginia, Cimaz, Rolando
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3684148/
https://ncbi.nlm.nih.gov/pubmed/23124805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.37776
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares